Loss of expression of HDAC-recruiting methyl-CpG-binding domain proteins in human cancer

2001

Loss of HDAC-recruiting proteins in cancer

Sample size: 71 publication Evidence: moderate

Author Information

Author(s): Müller-Tidow C, Kügler K, Diederichs S, Klümpen S, Möller M, Vogt U, Metzger R, Schneider P M, Berdel W E, Serve H

Primary Institution: Department of Medicine, Hematology and Oncology, University of Münster, Germany

The study investigates the expression levels of methyl-CpG-binding domain proteins MeCP2 and MBD2 in various human tumors.

The significant loss of MeCP2 and MBD2 expression in human cancers suggests a potential role in the development of solid tumors.

Expression levels of MBD2 and MeCP2 were significantly reduced in the majority of primary tumors.
Western blot analyses indicated reduced MeCP2 protein in a significant percentage of non-small-cell lung cancer patients.
In acute myelogenous leukaemia, expression levels were only slightly reduced.
Early-stage non-small-cell lung cancer showed significantly lower expression of MeCP2 and MBD2 in squamous cell carcinoma compared to other types.

In many cancers, important proteins that help control gene activity are missing, which might help tumors grow.

mRNA expression analysis using quantitative real-time RT-PCR and Western blot analyses.

The study primarily focuses on solid tumors and may not represent all cancer types.

Included various primary human tumors and specific patient groups with non-small-cell lung cancer and acute myelogenous leukaemia.

0.03 and 0.01

p=0.03 and p=0.01

Access the complete publication on the publisher's website